UiPath (NYSE:PATH) Shares Down 0.4%

UiPath Inc. (NYSE:PATH - Get Free Report)'s share price fell 0.4% during trading on Tuesday . The stock traded as low as $20.10 and last traded at $20.22. 969,519 shares were traded during mid-day trading, a decline of 88% from the average session volume of 8,036,072 shares. The stock had previously closed at $20.31.

Analyst Upgrades and Downgrades

Several brokerages have commented on PATH. Evercore ISI boosted their price target on shares of UiPath from $24.00 to $27.00 and gave the stock an "in-line" rating in a research report on Thursday, March 14th. Needham & Company LLC restated a "buy" rating and set a $30.00 price objective on shares of UiPath in a report on Wednesday, March 20th. Royal Bank of Canada restated a "sector perform" rating and set a $29.00 price objective on shares of UiPath in a report on Monday, April 1st. Morgan Stanley boosted their price objective on UiPath from $17.00 to $25.00 and gave the stock an "equal weight" rating in a report on Thursday, March 14th. Finally, KeyCorp started coverage on UiPath in a report on Monday, April 8th. They set an "overweight" rating and a $27.00 price objective on the stock. Nine investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $27.41.

UiPath Stock Down 2.0 %

The company has a market capitalization of $11.33 billion, a P/E ratio of -117.11 and a beta of 1.01. The firm has a 50-day moving average price of $20.88 and a two-hundred day moving average price of $22.09.

UiPath (NYSE:PATH - Get Free Report) last posted its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The company had revenue of $405.25 million during the quarter, compared to analysts' expectations of $383.32 million. On average, analysts predict that UiPath Inc. will post -0.04 EPS for the current fiscal year.

Insider Activity

In related news, CFO Ashim Gupta sold 40,000 shares of the company's stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $21.66, for a total value of $866,400.00. Following the completion of the transaction, the chief financial officer now directly owns 660,762 shares in the company, valued at $14,312,104.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders sold 96,000 shares of company stock valued at $2,023,440. 22.37% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PATH. Royal London Asset Management Ltd. raised its stake in UiPath by 5.9% during the third quarter. Royal London Asset Management Ltd. now owns 139,544 shares of the healthcare company's stock worth $2,388,000 after acquiring an additional 7,742 shares in the last quarter. Swiss National Bank raised its stake in UiPath by 4.9% during the fourth quarter. Swiss National Bank now owns 1,211,500 shares of the healthcare company's stock worth $30,094,000 after acquiring an additional 56,600 shares in the last quarter. Vestmark Advisory Solutions Inc. acquired a new position in UiPath during the fourth quarter worth $15,543,000. O Shaughnessy Asset Management LLC acquired a new position in UiPath during the third quarter worth $203,000. Finally, Invesco Ltd. raised its stake in UiPath by 2.8% during the third quarter. Invesco Ltd. now owns 399,181 shares of the healthcare company's stock worth $6,830,000 after acquiring an additional 10,863 shares in the last quarter. 62.50% of the stock is currently owned by institutional investors and hedge funds.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.